公开(公告)号：US20240116900A1

公开(公告)日：2024-04-11

申请号：US18250466

申请日：2021-10-29

Applicant: NOVARTIS AG

Inventor： Simona COTESTA ,  Heng GE ,  Marc GERSPACHER ,  Catherine LEBLANC ,  Bo LIU ,  Edwige Liliane Jeanne LORTHIOIS ,  Rainer MACHAUER ,  Robert MAH ,  Tanja MEISTER ,  Christophe MURA ,  Pascal RIGOLLIER ,  Nadine SCHNEIDER ,  Stefan STUTZ ,  Andrea VAUPEL ,  Nicolas WARIN ,  Rainer WILCKEN ,  Lijun XUE ,  Marie-Anne LOZAC'H ,  Ross STRANG

IPC: C07D403/14

CPC classification number: C07D403/14

Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.

公开(公告)号：US20150342951A1

公开(公告)日：2015-12-03

申请号：US14365512

申请日：2012-12-14

Applicant: NOVARTIS AG

Inventor： Nigel Graham COOKE ,  Paulo Antonio FERNANDES GOMES DOS SANTOS ,  Pascal FURET ,  Christina HEBACH ,  Klemens HOGENAUER ,  Gregory HOLLINGWORTH ,  Christoph KALIS ,  Ian LEWIS ,  Alexander Baxter SMITH ,  Nicolas SOLDERMANN ,  Frederic STAUFFER ,  Ross STRANG ,  Frank STOWASSER ,  Nicola TUFFILLI ,  Anette VON MATT ,  Romain WOLF ,  Frederic ZECRI

IPC: A61K31/519 ,  A61K31/551 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/517

CPC classification number: A61K31/519 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  C07D239/74 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D413/14 ,  C07D487/08 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414

Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

Abstract translation: 本发明涉及PI3K抑制剂的新用途，其中所述抑制剂对PI3K同种型δ具有抑制作用，用于治疗患有选自疟疾，利什曼病，锥虫病，弓形虫病和/或神经囊尾erc病的疾病或病症的受试者的免疫病理学， 通过功能抑制受感染受试者的TLR9。